KRAS and endometrial cancer: ADMET analysis of 5-fluorouracil makes it a suitable candidate for treating Type 1 endometrial cancer as it is unable to cross the BBB and have better efficacy with the mutated proteins of KRAS gene compared to ifosfamide.